Skip to main content

Table 1 Cell cycle phase proportions in ER + BC cells with or without TAS-120 treatment

From: Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells

Cell lines

Treatment

Sub G1%

G1%

S%

G2%

CAMA1

DMSO

1.1 ± 0.3

46.6 ± 2.8

33.5 ± 1.0

14.7 ± 2.2

 

FGF2

0.8 ± 0.1

64.7 ± 1.6

17.3 ± 0.6

13.7 ± 0.6

 

FGF2 + TAS-120

1.1 ± 0.4

49.2 ± 3.9

32.8 ± 3.5

13.0 ± 0.9

MDA-MB-134

DMSO

0.9 ± 0.5

51.7 ± 2.7

38.1 ± 2.3

7.8 ± 0.7

 

FGF2

1.0 ± 0.5

81.8 ± 3.1

9.6 ± 1.2

5.9 ± 0.2

 

FGF2 + TAS-120

0.3 ± 0.1

53.0 ± 1.1

37.8 ± 0.4

7.2 ± 0.4

MCF7

DMSO

3.8 ± 0.6

67.4 ± 2.9

16.5 ± 0.5

12,9 ± 1.8

 

FGF2

2.4 ± 0.2

60.0 ± 1.7

26.3 ± 2.3

12.5 ± 3.9

 

FGF2 + TAS-120

3.6 ± 0.8

72.6 ± 0.4

13.9 ± 1.0

10.9 ± 1.2

T47D

DMSO

3.5 ± 0.2

69.1 ± 1.2

20.3 ± 0.7

6.2 ± 0.5

 

FGF2

3.5 ± 0.7

56.4 ± 2.2

32.5 ± 1.4

6.9 ± 0.7

 

FGF2 + TAS-120

3.8 ± 0.1

72,6 ± 1.4

17.8 ± 1.1

5.9 ± 1.3

  1. The cells were collected from 2D cultures after being exposed to FGF2 (25ng/ml) with or without TAS-120 (1.0 µM) for 24 h, followed by PI staining-based flow cytometry analysis. The proportions of each phase were determined by Flowjo V10.3